Lianbio (LIANY) Stock Price & Analysis

Lianbio (LIANY) rose 0.00% to USD 0.04 as of September 8, 2026 at 17:20 UTC, according to Nexqual real-time market data.

LIANY last closed at USD 0.04; the session ranged USD 0.04–0.04 on volume of 7,219 shares. Market capitalization is —, with a 52-week range of USD 0.02–0.18 (PNK). Source: Nexqual, September 8, 2026 at 17:20 UTC.

Key Statistics (as of September 8, 2026 at 17:20 UTC)

Technical Analysis (LIANY)

Nexqual's technical model rates LIANY "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of September 8, 2026 at 17:20 UTC.

From Lianbio's Latest SEC 10-K Filing (filed 2023-03-28)

Key Strengths & Strategy (as disclosed to the SEC)

• We estimate there are approximately 1.1 million to 2.8 million HCM patients in China, with approximately two-thirds of patients having oHCM, and one-third of patients having nHCM.
• Tarsus submitted a New Drug Application ("NDA") to the FDA, with a target action date for the Prescription Drug User Fee Act ("PDUFA") of August 25, 2023.
• With operations in China, Asia Pacific, and the United States, we have built a cross-border platform to provide our licensing partners access to our regulatory, development, and commercial expertise in China and other Asian markets.
• We believe that enrolling patients in China in a global Phase 3 clinical trial may expedite the global development program as well as enable us to seek regulatory approval in China.

Partnerships

• Our pipeline Cardiovascular Mavacamten for the potential treatment of HCM We have partnered with MyoKardia, Inc. ("MyoKardia," now a wholly owned subsidiary of Bristol-Myers Squibb ("BMS")) to develop and commercialize mavacamten in Greater China and other Asian markets.
• Ophthalmology TP-03 for the potential treatment of demodex blepharitis and meibomian gland disease We have partnered with Tarsus Pharmaceuticals, Inc. ("Tarsus") to develop and commercialize TP-03 (lotilaner ophthalmic solution, 0.25%) in Greater China.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 17:20 UTC. This page is informational and not investment advice.